Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.

Monika BratovaJana SkrickovaMagda MatusikovaKarolina HrabcovaLibor HavelLeona KoubkovaMichal HrnciarikJana KrejciOndrej FischerMartin SvatonKristian Brat

Published in: Journal of cancer research and clinical oncology (2023)

We concluded that the treatment success in first-line therapies in patients with NSCLC may predict survival benefits in the subsequent lines, particularly in EGFR- or ALK-positive disease and immunotherapy-treated patients.

Keyphrases

small cell lung cancer
end stage renal disease
newly diagnosed
randomized controlled trial
systematic review
ejection fraction
chronic kidney disease
epidermal growth factor receptor
tyrosine kinase
replacement therapy